OmniAb is evolving from an early-stage biotech to a scalable platform company, supported by milestone-driven partnerships like the recent deal with Eli Lilly. The company has 110 partners and 425 programs, generating predictable milestone revenues with $340 million in clinical-stage milestones and a total milestone pool exceeding $3 billion. The collaboration with Eli Lilly validates OmniAb’s technology and improves its 2026 cash guidance to $49–$53 million. The company’s valuation remains at a premium due to its scalable platform and upcoming catalysts from partner clinical readouts and program graduations.
China's 10-year government bond yield dropped to 1.67%, its lowest since July 2025, driven by disappointing economic data and expectations of more stimulus from Beijing. Key indicators like industrial production and retail sales fell short of forecas...
Unitree Robotics, a Chinese humanoid robot maker, saw its shares jump 542% on its Shanghai stock market debut, raising about 6.1 billion yuan ($905 million) in its IPO. The company, known for its agile robots capable of backflips and dancing, attract...
SoundHound reported a strong Q2 with revenue up 45% year-over-year to $61.9 million, driven by major enterprise deals and improved gross margins reaching 58.4%. The company is advancing its AI voice software business through the launch of its OASYS a...
Globant initially forecasted 2026 revenue growth but later revised its outlook to a slight year-over-year decline, causing a sharp drop in its stock price. This reversal prompted Levi & Korsinsky to investigate potential securities law violations on ...
Bicara Therapeutics is progressing its Phase 3 trial of ficerafusp alfa for head and neck cancer, expecting interim results by mid-2027 that could support accelerated approval. The company holds nearly $500 million in cash and securities, funding ope...
